Business Description
BeOne Medicines Ltd
NAICS : 541714
SIC : 2834
ISIN : US07725L1026
Share Class Description:
ONC: ADRTotal Employee Number:
12,000Compare
Compare
Traded in other countries / regions
ONC.USA688235.China06160.Hong KongIJ0.GermanyB1ME34.BrazilBGNEN.Mexico IPO Date
2016-02-03Description
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes mainly with AbbVie and AstraZeneca. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 4.46 | |||||
Equity-to-Asset | 0.56 | |||||
Debt-to-Equity | 0.22 | |||||
Debt-to-EBITDA | 0.97 | |||||
Interest Coverage | 7.05 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 6.99 | |||||
Beneish M-Score | -2.78 | |||||
WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 50.8 | |||||
3-Year Book Growth Rate | -2.2 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 70.72 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 17.39 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 68.26 | |||||
9-Day RSI | 69.93 | |||||
14-Day RSI | 69.95 | |||||
3-1 Month Momentum % | 7.76 | |||||
6-1 Month Momentum % | 1.1 | |||||
12-1 Month Momentum % | 5.5 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.4 | |||||
Quick Ratio | 3.06 | |||||
Cash Ratio | 2.41 | |||||
Days Inventory | 327.85 | |||||
Days Sales Outstanding | 53.52 | |||||
Days Payable | 227.08 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2 | |||||
Shareholder Yield % | -0.12 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 88.89 | |||||
Operating Margin % | 15.06 | |||||
Net Margin % | 10.7 | |||||
EBITDA Margin % | 19.18 | |||||
FCF Margin % | 21.36 | |||||
OCF Margin % | 24.21 | |||||
ROE % | 14.77 | |||||
ROA % | 8.23 | |||||
ROIC % | 25.52 | |||||
3-Year ROIIC % | 498.32 | |||||
ROC (Joel Greenblatt) % | 55.06 | |||||
ROCE % | 17.29 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 67.23 | |||||
Forward PE Ratio | 47.49 | |||||
PE Ratio without NRI | 32.12 | |||||
Price-to-Owner-Earnings | 65.23 | |||||
PS Ratio | 7.11 | |||||
PB Ratio | 8.21 | |||||
Price-to-Tangible-Book | 8.31 | |||||
Price-to-Free-Cash-Flow | 33.1 | |||||
Price-to-Operating-Cash-Flow | 29.21 | |||||
EV-to-EBIT | 38.51 | |||||
EV-to-Forward-EBIT | 37.67 | |||||
EV-to-EBITDA | 33.43 | |||||
EV-to-Forward-EBITDA | 31.3 | |||||
EV-to-Revenue | 6.41 | |||||
EV-to-Forward-Revenue | 5.81 | |||||
EV-to-FCF | 30.02 | |||||
Price-to-GF-Value | 1 | |||||
Price-to-Median-PS-Value | 0.36 | |||||
Price-to-Graham-Number | 3.44 | |||||
| Price-to-Net-Current-Asset-Value | 13.22 | |||||
| Price-to-Net-Cash | 38.74 | |||||
Earnings Yield (Greenblatt) % | 2.6 | |||||
FCF Yield % | 3.03 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ONC
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
BeOne Medicines Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 6,128.963 | ||
| EPS (TTM) ($) | 5.59 | ||
| Beta | 0.4863 | ||
| 3-Year Sharpe Ratio | 0.41 | ||
| 3-Year Sortino Ratio | 0.73 | ||
| Volatility % | 29.03 | ||
| 14-Day RSI | 69.95 | ||
| 14-Day ATR ($) | 9.605431 | ||
| 20-Day SMA ($) | 351.879 | ||
| 12-1 Month Momentum % | 5.5 | ||
| 52-Week Range ($) | 253.9475 - 385.22 | ||
| Shares Outstanding (Mil) | 113.12 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
BeOne Medicines Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
BeOne Medicines Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-02-26 08:00 | In 184 days | ||
| Annual report for 2026 | 2027-02-26 | In 183 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-26 | In 183 days | ||
| Third quarter earnings conference call for 2026 | 2026-11-06 08:00 | In 72 days | ||
| Third quarter earnings results for 2026 | 2026-11-06 | In 71 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-05 08:00 | 323.01 (+0.63%) | ||
| Second quarter earnings results for 2026 | 2026-08-05 | 323.01 (+0.63%) | ||
| General meeting for 2026 | 2026-06-11 09:30 | 263.61 (-1.21%) | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-08 10:00 | 270.10 (-1.85%) | ||
| First quarter earnings conference call for 2026 | 2026-05-06 08:00 | 297.49 (+0.16%) |
Show
Entries
BeOne Medicines Ltd Frequently Asked Questions
What is BeOne Medicines Ltd(ONC)'s stock price today?
The current price of ONC is $375.80. The 52 week high of ONC is $385.22 and 52 week low is $253.95.
When is next earnings date of BeOne Medicines Ltd(ONC)?
The next earnings date of BeOne Medicines Ltd(ONC) is 2026-11-06 Est..
Does BeOne Medicines Ltd(ONC) pay dividends? If so, how much?
BeOne Medicines Ltd(ONC) does not pay dividend.
Guru Commentaries on NAS:ONC
2025 Q3
What the manager wrote
BeOne Medicines Ltd. reported a strong quarter and raised FY25 guidance, driven by strong momentum from its key growth driver, Brukinsa, which continues to gain market share from its competitors. Management expects positive free cash flow in 2025, indicating a solid outlook for the company. This growth trajectory and market position suggest that BeOne Medicines is well-positioned for future success.
2025 Q3
What the manager wrote
BeOne Medicines Ltd. reported a strong quarter and raised FY25 guidance, driven by strong momentum from its key growth driver, Brukinsa, which continues to gain market share from its competitors. Management expects positive free cash flow in 2025.
Press Release
Articles on BeOne Medicines Ltd
Headlines
See More- 1
Aug 25, 2026
Jazz wins FDA nod for cancer therapy developed with BeOne, Zymeworks
Seeking Alpha • 9:46am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers